Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
08:35am, Friday, 14'th Mar 2025
Nektar Therapeutics (NKTR) came out with quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
01:15pm, Thursday, 13'th Mar 2025
NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected.
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
09:31pm, Wednesday, 12'th Mar 2025
While the top- and bottom-line numbers for Nektar (NKTR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
09:31pm, Wednesday, 12'th Mar 2025
The headline numbers for Nektar (NKTR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript
08:00pm, Wednesday, 12'th Mar 2025
Nektar Therapeutics (NASDAQ:NKTR ) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Vivian Wu - Investor Relations Howard Robin - President & Chief Executive Officer Bri
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
04:15pm, Wednesday, 12'th Mar 2025
SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable sec
SAN FRANCISCO , March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 202
SAN FRANCISCO , Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in pa
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
07:00am, Monday, 24'th Feb 2025
SAN FRANCISCO , Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, F
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
07:00am, Monday, 24'th Feb 2025
-- TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK , Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an inte
SAN FRANCISCO , Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleuk
Down -38.51% in 4 Weeks, Here's Why Nektar (NKTR) Looks Ripe for a Turnaround
10:36am, Friday, 07'th Feb 2025
Nektar (NKTR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co
Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
10:55am, Friday, 31'st Jan 2025
Nektar (NKTR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall St
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
09:05am, Friday, 31'st Jan 2025
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.
SAN FRANCISCO , Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in pa
